Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

IMRX
Immuneering Corporation Class A Common Stock
stock NASDAQ

At Close
Oct 24, 2025 3:59:30 PM EDT
6.03USD+7.105%(+0.40)1,079,452
0.00Bid   0.00Ask   0.00Spread
Pre-market
Oct 27, 2025 8:57:30 AM EDT
6.12USD+1.493%(+0.09)946
After-hours
Oct 24, 2025 4:46:30 PM EDT
6.05USD+0.332%(+0.02)5,798
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 24, 2022
06:50AM EST  Immuneering Announces Participation in Upcoming Investor Conferences   GlobeNewswire Inc
Jan 19, 2022
08:00AM EST  PepGen, Inc.,a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed Laurie Keating as Chair of the companys Board of Directors.   GlobeNewswire Inc
Jan 18, 2022
06:50AM EST  Immuneering Strengthens Board of Directors with the Appointment of   GlobeNewswire Inc
Jan 7, 2022
01:07PM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022   Benzinga
01:02PM EST  Piper Sandler Initiates Coverage On Immuneering with Overweight Rating, Announces Price Target of $41   Benzinga
Jan 6, 2022
04:14PM EST  Immuneering Reports Preclinical Data On IMM-1-104 In NRAS Mutant Melanoma Model; Says 'Preclinical Data Suggest IMM-1-104 May Offer Unique Therapeutic Advantage Compared with Binimetinib in NRAS Mutant Tumors'   Benzinga
04:10PM EST  Preclinical Data Suggest IMM-1-104 May Offer Unique Therapeutic Advantage Compared with Binimetinib in NRAS Mutant Tumors   GlobeNewswire Inc
Jan 5, 2022
11:07AM EST  Stocks That Hit 52-Week Lows On Wednesday   Benzinga
Jan 3, 2022
06:50AM EST  Immuneering Appoints Rimma Steinhertz, Ph.D., PMP as Vice   GlobeNewswire Inc
Dec 16, 2021
06:51AM EST  Immuneering Added To The Nasdaq Biotechnology Index   Benzinga
06:50AM EST  Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) effective prior to the market open on Monday, December 20, 2021.   GlobeNewswire Inc
Nov 18, 2021
06:35AM EST  Immuneering Announces Participation in December Investor Conferences   GlobeNewswire Inc
Nov 10, 2021
11:51AM EST  How Bad Are Immuneering's Earnings? | Return On Capital Employed   Benzinga
06:50AM EST  Immuneering to Participate in Jefferies 2021 London Healthcare   GlobeNewswire Inc
Nov 9, 2021
11:28AM EST  Immuneering Q3 EPS $(0.47) Up From $(0.89) YoY   Benzinga
06:30AM EST  Successfully completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024   GlobeNewswire Inc
Oct 11, 2021
06:53AM EDT  Immuneering Reports Compelling Preclinical Data On IMM-1-104 At AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics   Benzinga
06:50AM EDT  Preclinical Data Demonstrated Broad Antitumor Activity Across KRAS, NRAS and BRAF Mutant Tumor Models, Established Novel Mechanism of Action for its Dual MEK Inhibition and Showed Synergies with Sotorasib in KRAS-G12C Mutant Pancreatic Cancer   GlobeNewswire Inc
Oct 1, 2021
06:51AM EDT  Immuneering Reports Will Present Preclinical Data Across Several Poster Presentations At AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Oct. 7-10   Benzinga
06:50AM EDT  Preclinical Data Demonstrates Broad Antitumor Activity of IMM-1-104 Across RAS and RAF Mutant Tumors and Highlights Mechanistic Aspects of its Dual MEK Inhibition   GlobeNewswire Inc
Sep 21, 2021
08:20AM EDT  The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data   Benzinga
Sep 20, 2021
04:10PM EDT  Immuneering Announces Inclusion in the Russell 2000 Index   Benzinga
04:10PM EDT  Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced that Immuneering Corporation has been selected to be added to the Russell 2000Index effective September 20, 2021, after the close of the U.S. equity markets.   GlobeNewswire Inc
Sep 9, 2021
08:17AM EDT  The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization   Benzinga
06:36AM EDT  Immuneering Q2 Sales $660.00K Up From $480.80K YoY   Benzinga
06:35AM EDT  Immuneering Q2 EPS $(1.61) Down From $(0.73) YoY   Benzinga
06:30AM EDT  Recently completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024   GlobeNewswire Inc
Sep 2, 2021
04:05PM EDT  Immuneering to Participate in September Investor Conferences   GlobeNewswire Inc
Aug 24, 2021
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2021   Benzinga
07:27AM EDT  Cowen & Co. Initiates Coverage On Immuneering with Outperform Rating   Benzinga
07:22AM EDT  Guggenheim Initiates Coverage On Immuneering with Buy Rating, Announces Price Target of $42   Benzinga
07:14AM EDT  Morgan Stanley Initiates Coverage On Immuneering with Equal-Weight Rating, Announces Price Target of $39   Benzinga
06:08AM EDT  Jefferies Initiates Coverage On Immuneering with Buy Rating, Announces Price Target of $50   Benzinga
Aug 6, 2021
07:42AM EDT  The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO   Benzinga
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Jul 30, 2021
02:24PM EDT  Oncology-Focused Biotech Immuneering Jumps To Wall Street With $112M IPO   Benzinga
11:27AM EDT  Immuneering Shares Open For Trade At $19.50; IPO Priced At $15/Share   Benzinga
09:15AM EDT  Immuneering Shares Will Open For Quote At 10:35 a.m. EDT, Expected To Open For Trade After 10:45 a.m. EDT; IPO Priced At $15/Share   Benzinga
07:54AM EDT  The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs   Benzinga
Jul 20, 2021
06:47AM EDT  Immuneering Appoints Michael Bookman as General Counsel and Secretary   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC